The e-mails show that the companies paid as much as $25,000 to attend any given meeting of the panel, which had been set up by two academics to provide advice to the FDA on how to weigh the evidence from clinical trials. A leading FDA official later called the group “an essential collaborative effort.”
Patient advocacy groups said the electronic communications suggest that the regulators had become too close to the companies trying to crack into the $9 billion painkiller market in the United States. FDA officials who regulate painkillers sat on the steering committee of the panel, which met in private, and co-wrote papers with employees of pharmaceutical companies.
The FDA has been criticized for failing to take precautions that might have averted the epidemic of addiction to prescription drugs including Oxycontin and other opioids.
The Supreme Court on May 4 reinstated mail-order access to the widely used abortion drug mifepristone,...
At the MAHA Institute's "Mental Health & Overmedicalization Summit" in the nation's capital, the Health and...
Three people have died in an outbreak of a dangerous respiratory virus on a cruise ship...
